SCHEMBL24309560

SCHEMBL24309560

Cc1cccc(C)c1-c1cc(Oc2ccc(CC(=O)O)cc2)nc(NS(=O)(=O)c2cnn(C)c2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 1/20 0.38
▸ TSHR P16473 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ PTGDR2 Q9Y5Y4 2/20 0.35
▸ PTGIR P43119 1/20 0.35
▸ KDR P35968 3/20 0.35
▸ EGFR P00533 1/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ CYP26A1 O43174 2/20 0.35
▸ CYP26B1 Q9NR63 1/20 0.35
▸ RORC P51449 1/20 0.34
▸ LMNA P02545 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GLA P06280 1/20 0.34
▸ CASP6 P55212 1/20 0.34
▸ MET P08581 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ HTR1A P08908 1/20 0.34
▸ HTR7 P34969 1/20 0.34
▸ SRD5A2 P31213 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566776 1.00 F2 (0.38) F2TSHRSMN1; SMN2PTGDR2PTGIR
SCHEMBL26810204 0.93 PDE4B (0.39) TSHRSMN1; SMN2KDREGFRFGFR1
SCHEMBL26810202 0.92 LMNA (0.36) TSHRSMN1; SMN2KDREGFRFGFR1
SCHEMBL29566838 0.90 GFER (0.39) TSHRSMN1; SMN2KDREGFRFGFR1
SCHEMBL24310039 0.90 GFER (0.39) TSHRSMN1; SMN2KDREGFRFGFR1
SCHEMBL29566747 0.90 BRD4 (0.33) TSHRSMN1; SMN2PTGDR2KDREGFR
SCHEMBL26810198 0.90 HSD17B10 (0.40) SMN1; SMN2ALDH1A1POLB
SCHEMBL24310798 0.90 BRD4 (0.33) TSHRSMN1; SMN2PTGDR2KDREGFR
SCHEMBL24310345 0.89 TSHR (0.43) TSHRSMN1; SMN2KDREGFRFGFR1
SCHEMBL29566612 0.89 TSHR (0.43) TSHRSMN1; SMN2KDREGFRFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B F2 4469/4885TSHR 1755/4885SMN1; SMN2 4847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback